| Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials CT Trialists The Lancet 376 (9753), 1670-1681, 2010 | 8638* | 2010 |
| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5396 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2799 | 2020 |
| The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. B Mihaylova, J Emberson, L Blackwell, A Keech, J Simes, EH Barnes, ... Lancet (London, England) 380 (9841), 581-590, 2012 | 2328 | 2012 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1693 | 2020 |
| Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant SA Madhi, V Baillie, CL Cutland, M Voysey, AL Koen, L Fairlie, ... New England Journal of Medicine 384 (20), 1885-1898, 2021 | 1386 | 2021 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1353 | 2021 |
| Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection S Feng, DJ Phillips, T White, H Sayal, PK Aley, S Bibi, C Dold, M Fuskova, ... Nature medicine 27 (11), 2032-2040, 2021 | 1076 | 2021 |
| SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses W Dejnirattisai, J Huo, D Zhou, J Zahradník, P Supasa, C Liu, ... Cell 185 (3), 467-484. e15, 2022 | 940 | 2022 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 743 | 2021 |
| External validation of multivariable prediction models: a systematic review of methodological conduct and reporting GS Collins, JA de Groot, S Dutton, O Omar, M Shanyinde, A Tajar, ... BMC medical research methodology 14, 1-11, 2014 | 680 | 2014 |
| T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial KJ Ewer, JR Barrett, S Belij-Rammerstorfer, H Sharpe, R Makinson, ... Nature medicine 27 (2), 270-278, 2021 | 607 | 2021 |
| Community treatment orders for patients with psychosis (OCTET): a randomised controlled trial T Burns, J Rugkåsa, A Molodynski, J Dawson, K Yeeles, ... The Lancet 381 (9878), 1627-1633, 2013 | 437 | 2013 |
| Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial K Rajamani, PG Colman, LP Li, JD Best, M Voysey, MC D'Emden, ... The Lancet 373 (9677), 1780-1788, 2009 | 411* | 2009 |
| Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority … SAC Clemens, L Weckx, R Clemens, AVA Mendes, AR Souza, ... The Lancet 399 (10324), 521-529, 2022 | 396 | 2022 |
| Safety and immunogenicity of novel adenovirus type 26–and modified vaccinia ankara–vectored ebola vaccines: a randomized clinical trial ID Milligan, MM Gibani, R Sewell, EA Clutterbuck, D Campbell, E Plested, ... Jama 315 (15), 1610-1623, 2016 | 378 | 2016 |
| Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses JR Barrett, S Belij-Rammerstorfer, C Dold, KJ Ewer, PM Folegatti, ... Nature medicine 27 (2), 279-288, 2021 | 345 | 2021 |
| Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) A Flaxman, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, ... The Lancet 398 (10304), 981-990, 2021 | 272 | 2021 |
| Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: an individual participant data meta-analysis CA Crowther, PF Middleton, M Voysey, L Askie, L Duley, PG Pryde, ... PLoS medicine 14 (10), e1002398, 2017 | 224 | 2017 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial J Frater, KJ Ewer, A Ogbe, M Pace, S Adele, E Adland, J Alagaratnam, ... The lancet HIV 8 (8), e474-e485, 2021 | 223 | 2021 |
Professor Sir Andrew PollardUniversity of Oxford在 paediatrics.ox.ac.uk 的电子邮件经过验证
